financetom
Business
financetom
/
Business
/
Impinj Prices Upsized Convertible Senior Notes Offering
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Impinj Prices Upsized Convertible Senior Notes Offering
Sep 4, 2025 6:50 AM

09:26 AM EDT, 09/04/2025 (MT Newswires) -- Impinj ( PI ) said Thursday it has priced an upsized private offering of $170 million worth of 0% convertible senior notes due 2029.

The offering, expanded from $150 million, will also allow the initial buyers the option to buy up to an additional $20 million worth of the notes within 13 days of issuance, the company said.

Net proceeds of roughly $164.2 million, or about $183.6 million if the initial purchasers exercise their option, will be allocated toward exchanging $190 million worth of Impinj's ( PI ) outstanding 1.125% convertible senior notes due 2027, Impinj ( PI ) added.

The notes will be convertible at an preliminary rate of 3.7398 Impinj ( PI ) common shares per $1,000 worth of notes, equivalent to a conversion price of roughly $267.39 per share, the company said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Lexeo Says FDA Open to Application Submission for Accelerated Approval of Friedreich Ataxia Cardiomyopathy Treatment
Lexeo Says FDA Open to Application Submission for Accelerated Approval of Friedreich Ataxia Cardiomyopathy Treatment
Oct 7, 2025
07:23 AM EDT, 10/07/2025 (MT Newswires) -- Lexeo Therapeutics ( LXEO ) said Tuesday the US Food and Drug Administration has indicated openness to a biologics license application submission for accelerated approval of its LX2006 candidate for the treatment of Friedreich ataxia cardiomyopathy. The submission will include interim clinical data from ongoing phase I/II studies of LX2006 pooled with new...
Eli Lilly Reports 4 Years of Sustained Remission in Patients With Ulcerative Colitis
Eli Lilly Reports 4 Years of Sustained Remission in Patients With Ulcerative Colitis
Oct 7, 2025
07:21 AM EDT, 10/07/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Tuesday that data from its phase 3 open-label extension study showed that its drug Omvoh, or mirikizumab-mrkz, achieved sustained clinical, endoscopic and steroid-free remission over four years in patients with moderate to severely active ulcerative colitis. After four years of treatment, the company said that 78% of...
Shell Collaborates With Indonesia Government to Address Gasoline Supply Issues
Shell Collaborates With Indonesia Government to Address Gasoline Supply Issues
Oct 7, 2025
07:15 AM EDT, 10/07/2025 (MT Newswires) -- Shell (SHEL) is working with the Indonesian government and other stakeholders to restock gasoline at its fuel stations as quickly as possible, Bloomberg reported Tuesday, citing a company spokesperson. The company's retail stations in Indonesia are experiencing gasoline shortages for the second time in less than two months, due to ongoing import restrictions,...
Canadian retailer Kits Eyecare misses Q3 sales estimates
Canadian retailer Kits Eyecare misses Q3 sales estimates
Oct 7, 2025
Overview * Kits Eyecare ( KTYCF ) Q3 revenue up 25.1% yr/yr to C$52.4 mln, missing estimates * Adjusted EBITDA for Q3 increased to approximately 5.2% of revenue * New customers grew 27.6% yr/yr to about 99,000 Outlook * Company did not provide specific guidance for future quarters or year Result Drivers * CUSTOMER GROWTH - New customers increased by...
Copyright 2023-2026 - www.financetom.com All Rights Reserved